Compare Iris Energy Limited (IREN) vs Tango Therapeutics Inc. (TNGX) Price & Performance

IREN trades at $34.80, showing no change in the last 24 hours. The stock faces bearish technical signals despite bullish oscillators, with key support at $34. Recent earnings misses and a negative net income margin of -99.38% highlight financial strain, though revenue grew to $501M in 2025. Analyst sentiment remains strongly positive with a consensus price target of $81.00, driven by the company's pivot to AI infrastructure and major contracts with Microsoft and NVIDIA.

The outlook is bifurcated: substantial upside exists if IREN executes its AI transition, but high valuation ratios and persistent losses pose risks. Investors should weigh the aggressive growth projections against current profitability challenges and capital intensity.

TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.

Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.